Patents Examined by James C. Housel
  • Patent number: 6274327
    Abstract: This invention relates to new polypeptides which exhibit kinase activity or, more specifically, which show phosphoinositide (PI) 3-kinase activity. Such polypeptides are involved in pathways responsible for cellular growth and differentiation. An isolated polypeptide which possesses PI3-kinase activity when produced by recombinant production in insect cells is disclosed.
    Type: Grant
    Filed: May 27, 1998
    Date of Patent: August 14, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ian D. Hiles, Michael J. Fry, Ritu Dhand, Michael D. Waterfield, Peter J. Parker, Masayuki Otsu, George Panayoutou, Stefano Volinia, Ivan Gout
  • Patent number: 6254874
    Abstract: A live non-virulent vaccine composition and method for preparing the same comprising a virulent microorganismal strain which contains at least two mutations, wherein the first mutation results in an auxotrophic mutant which requires for proliferation, a nutrient which is normally available in the host tissues in an amount required by the auxotrophic mutant for proliferation and the second mutation results in the inability of the auxotrophic mutant to specifically transport the required nutrient from host-tissues into the auxotrophic mutant thereby producing an attenuated strain.
    Type: Grant
    Filed: April 13, 1995
    Date of Patent: July 3, 2001
    Assignee: President and Fellows of Harvard College
    Inventors: John J. Mekalanos, Karl E. Klose
  • Patent number: 6232116
    Abstract: Oral or peroral administration, including intragastrically, of killed whole pneumococci, lysate of pneumococci and isolated and purified PspA, as well as immunogenic fragments thereof, particularly when administered with an adjuvant such as cholera toxin provides protection in a host, animal or human, against pneumococcal infection, including colonization, and systemic infection, such as sepsis. The ability to elicit protection against pneumococcal colonization in a host prevents carriage among immunized individuals, which can lead to elimination of disease from the population as a whole.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 15, 2001
    Assignee: University of Alabama at Birmingham Research Foundation
    Inventors: David E. Briles, Larry S. McDaniel, Masafumi Yamamoto, Hiroshi Kiyono
  • Patent number: 6221659
    Abstract: Coagulation protein antagonists are disclosed, which include monoclonal-type antibodies and related cell lines disclosed for the production of specific, neutralizing antibodies against factors VII and VIIa and the tissue factor/factor VIIa bimolecular complex, which antibodies are useful for the prevention or treatment of thrombotic and related diseases, for immunoaffinity isolation and purification of factors VII and VIIa and the tissue factor/factor VIIa complex, and for determination of factors VII or VIIa and the tissue factor/factors VII or VIIa complex in a biological sample.
    Type: Grant
    Filed: January 16, 1998
    Date of Patent: April 24, 2001
    Assignee: Corvas Inc.
    Inventors: Howard R. Soule, Terence K. Brunck
  • Patent number: 6214560
    Abstract: Method for specific detection of one or more analytes in a sample. The method includes specifically associating any one or more analytes in the sample with a scattered-light detectable particle, illuminating any particle associated with the analytes with light under conditions which produce scattered light from the particle and in which light scattered from one or more particles can be detected by a human eye with less than 500 times magnification and without electronic amplification. The method also includes detecting the light scattered by any such particles under those conditions as a measure of the presence of the analytes.
    Type: Grant
    Filed: April 18, 1997
    Date of Patent: April 10, 2001
    Assignee: Genicon Sciences Corporation
    Inventors: Juan Yguerabide, Evangelina E. Yguerabide, David E. Kohne, Jeffrey T. Jackson
  • Patent number: 6211159
    Abstract: Purified and isolated nucleic acid molecules are provided which encode a FlaC flagellin protein of a strain of Campylobacter, particularly C. jejuni, or a fragment or an analog of the FlaC flagellin protein. The nucleic acid molecules may be used to produce proteins free of contaminants derived from bacteria normally containing the FlaA or FlaB proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecules, proteins encoded thereby and antibodies raised against the proteins, may be used in the diagnosis of infection.
    Type: Grant
    Filed: April 11, 1997
    Date of Patent: April 3, 2001
    Assignee: University of Toronto
    Inventors: Voon Loong Chan, Helena Louie
  • Patent number: 6203758
    Abstract: A micro-circuit for performing analyses of multimolecular interactions and for performing molecular syntheses, comprising: (a) a support; (b) at least one micro-electrode attached to the support, the micro-electrode being selectively electronically activated and the micro-electrode having a protective layer which is removable; (c) a binding entity for attachment to the at least one micro-electrode, the binding entity being capable of attachment to at least one micro-electrode when the protective layer has been removed; and (d) a power source being operatively connected to at least one micro-electrode for electronically activating at least one micro-electrode. The micro-circuit of the present invention also includes embodiments featuring a micro-circuit reader for detecting the interaction of the binding entity to a complementary probe, as well as methods for making and using the micro-circuit of the present invention.
    Type: Grant
    Filed: November 10, 1997
    Date of Patent: March 20, 2001
    Assignee: Bio-Pixel Ltd.
    Inventors: Robert Marks, Jean-Paul Lellouche
  • Patent number: 6204005
    Abstract: The present invention provides a method for determining qualitatively or quantitatively the presence of toxic congeners of polychlorinated biphenyl in a test sample. The method includes the steps of: providing a known quantity of antibodies to the toxic polychlorinated biphenyl congener; providing a competitor that will bind to said antibodies in competition with the toxic polychlorinated biphenyl congener and having a lower affinity to said antibodies than said antibodies have to the toxic polychlorinated biphenyl congener; incubating said antibodies and said competitor in the presence of a test sample; and detecting the presence of the toxic polychlorinated biphenyl toxic congener in the test sample.
    Type: Grant
    Filed: March 16, 1995
    Date of Patent: March 20, 2001
    Assignee: Ecochem Research, Inc.
    Inventors: Robert E. Carlson, Todd A. Swanson
  • Patent number: 6197599
    Abstract: A device comprises a solid support and multiple immobilized agents for protein detection is described. The immobilized agents are mainly proteins, such as antibodies and recombinant proteins. The immobilized agents can be synthesized peptides or other small chemicals. Agents are individually deposited in a predetermined order, so that each of the agents can be identified by the specific position it occupies on the support. The immobilized agents on the solid support retain their protein binding capability and specificity. Methods employing the device are extremely powerful in screening protein expression patterns, protein posttranslational modifications and protein—protein interactions.
    Type: Grant
    Filed: July 30, 1998
    Date of Patent: March 6, 2001
    Inventors: Guorong Chin, Yingyi Wang
  • Patent number: 6197929
    Abstract: The invention relates to an adjuvant product which is intended to improve the activity of a molecule when administered to a host, characterized in that it comprises at least one part of the P40 protein of Klebsiella pneumoniae or a protein having at least 80% homology with the P40 protein of Klebsiella pneumoniae. The invention also relates to nucleotide sequences which encode these peptides or proteins and to the use of these sequences as a medicament. More particularly, such DNA sequences can be used in compositions which are intended for immunization by the intramuscular or intradermal route.
    Type: Grant
    Filed: August 11, 1997
    Date of Patent: March 6, 2001
    Inventors: Hans Binz, Thierry Baussant, Jean-François Haeuw, Thien Nguyen Ngoc
  • Patent number: 6197494
    Abstract: An element and method for easily performing liquid assays are disclosed. The element uses capillary action to draw a predetermined volume of a liquid sample into a reaction chamber charged with reagent, where reaction between the liquid sample and the reagent is monitored.
    Type: Grant
    Filed: March 18, 1997
    Date of Patent: March 6, 2001
    Assignee: Cardiovascular Diagnostics, Inc.
    Inventor: Bruce Oberhardt
  • Patent number: 6191254
    Abstract: A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X1X1PX2X3X2P(X2X2P)nX2X3(X5)o; (SEQ ID NO: 23) X1X1PX2X3X4(X5)rPX2X3X3; (SEQ ID NO: 24) X1X1X3(PW)uX3X2X5X2X2X5X2(X5)o; and (SEQ ID NO: 25) X1X1X3X3X2P(X2X2P)nX2(X5)m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine X3 represents Arginine or Lysine; X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
    Type: Grant
    Filed: August 23, 1996
    Date of Patent: February 20, 2001
    Assignee: University of British Columbia
    Inventors: Timothy J. Falla, Robert E. W. Hancock, Monisha Gough
  • Patent number: 6190667
    Abstract: This invention relates to methods of screening molecules capable of inhibiting the survival of Helicobacter pylori in vivo by specifically inhibiting the activity of UreI, to the molecules identified by these methods, and to the use of these molecules to treat or prevent H. pylori infection.
    Type: Grant
    Filed: June 30, 1998
    Date of Patent: February 20, 2001
    Assignee: Institut Pasteur
    Inventors: Hilde De Reuse, Stéphane Skouloubris, Valérie Cussac, Agnès Labigne
  • Patent number: 6187547
    Abstract: A new method of measuring blood levels of immunophilin-binding pharmaceuticals, e.g., cyclosporins, rapamycins, and FK506 compounds is provided, comprising the novel step of displacing the pharmaceutical from its immunophilin by using a binding competitor, thereby eliminating the need for an extraction step and enhancing the simplicity and accuracy of the assay. Assay kits comprising a binding competitor and a receptor, e.g., a monoclonal antibody, which binds to the pharmaceutical but not significantly to the binding competitor are also provided, as are new uses of immunophilin-binding compounds as binding competitors in such assays.
    Type: Grant
    Filed: August 6, 1998
    Date of Patent: February 13, 2001
    Assignee: Novartis AG
    Inventors: François Legay, Roland Wenger
  • Patent number: 6184357
    Abstract: The present invention provides a human prostate-specific kallikrein (HPSK) and polynucleotides which identify and encode HPSK. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPSK and a method for producing HPSK. The invention also provides for agonists, antibodies, or antagonists specifically binding HPSK, and their use, in the prevention and treatment of diseases associated with the expression of HPSK. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPSK for the treatment of diseases associated with the expression of HPSK. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HPSK.
    Type: Grant
    Filed: March 3, 1999
    Date of Patent: February 6, 2001
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Surya K. Goli
  • Patent number: 6177281
    Abstract: The present invention relates to a simple immunochemical semi-quantitative assay method according to chromatography, which comprises trapping a certain amount of an analyte in a sample with a predetermined amount of a fixed antibody for the analyte before qualitative analysis of the analyte, the certain amount corresponding to the amount of the fixed antibody, and thereby decreasing a concentration of the analyte to be subjected to subsequent immunochemical qualitative determination, and an apparatus therefor.
    Type: Grant
    Filed: June 11, 1996
    Date of Patent: January 23, 2001
    Assignee: Teikoku Hormone Mfg. Co., Ltd.
    Inventor: Hideaki Manita
  • Patent number: 6177282
    Abstract: The invention relates to an immunoassays, binding assays, solid phase substrates (12) and other devices with an antigen or antibody or ligand or receptor (11) embedded into a solid phase substrate (12). The antigen or antibody is mixed with a molten thermoplastic and formed into the solid phase substrate (12).
    Type: Grant
    Filed: August 12, 1997
    Date of Patent: January 23, 2001
    Inventor: John A. McIntyre
  • Patent number: 6171801
    Abstract: One aspect of the present invention relates to a method for releasing a ligand from a complex thereof. The method comprises contacting a medium suspected of containing such complex with an effective amount of a compound effective in releasing the ligand. Another aspect of the present invention is an improvement in a method for the determination of an analyte that is a member of a specific binding pair in a sample suspected of containing such analyte. The method comprises the steps of (a) providing in an assay medium the sample and a binding partner for the analyte and (b) detecting the binding of the binding partner to the analyte. The improvement comprises including in the assay medium a compound of the invention in an amount sufficient to enhance the accuracy of the determination. The invention has particular application to a method for releasing mycophenolic acid from a complex thereof.
    Type: Grant
    Filed: July 17, 1997
    Date of Patent: January 9, 2001
    Assignee: Dade Behring Marburg GmbH
    Inventors: Mark A. Staples, Carolyn J. Haley, Richard F. Parrish, Wesley W. Zmolek
  • Patent number: 6168779
    Abstract: Methods, kits, and apparatus for locating, labelling, and accessing breast ducts are described. An orifice to one or more ductal networks is labelled using a specific binding substance, typically an antibody, specific for a tissue marker present on the orifice. Exemplary tissue markers include those present on the ductal epithelium, such as cytokeratins, including cytokeratin 8 and cytokeratin 18; E cadhedrin; and epithelial membrane antigen. Labelling of the ductal orifices permits reliable identification and access to each of the multiple ductal networks which may be present in an individual breast.
    Type: Grant
    Filed: September 16, 1997
    Date of Patent: January 2, 2001
    Assignee: The Regents of the University of California
    Inventors: Sanford H. Barsky, Susan M. Love
  • Patent number: 6165729
    Abstract: Electrochemiluminescent assay methods for determining an analyte of interest, which methods include forming one or more compositions which include, in the aggregate, (a) a sample to be tested for the analyte of interest, (b) a component capable of specifically binding with the analyte, (c) a label reagent which, when oxidized, is capable of electrochemiluminescence, (d) an amine which, when oxidized, forms a reducing agent, and (e) an electrolyte solution; subjecting such a composition containing the sample to conditions sufficient for specific binding to occur between the analyte of interest, if present, and one or more of the other components in the composition; thereafter, a composition containing the label reagent and amine, and reflecting the outcome of applying the aforementioned binding conditions, is exposed to conditions, such that both the label reagent and the amine are oxidized, the amine forms a reducing agent which interacts with the label reagent, electrochemiluminescence occurs, and the lumine
    Type: Grant
    Filed: April 15, 1994
    Date of Patent: December 26, 2000
    Assignee: Hyperion Catalysis International, Inc.
    Inventors: Jonathan Kent Leland, Michael Joseph Powell